Introduction
============

Although the incidence of gastric cancer (GC) is decreasing, it remains one of the main causes of cancer-related death in the world, with a high rate of tumor recurrence and distant metastasis.[@b1-cmar-10-3007],[@b2-cmar-10-3007] Early detection is important. However, early-stage GC is often clinically silent with nonspecific symptoms.[@b3-cmar-10-3007] Although there have been massive strides in surgery and postoperative treatment, the clinical outcomes for GC patients remain poor with high rates of late diagnosis.[@b4-cmar-10-3007],[@b5-cmar-10-3007] Thus, it is of vital importance to identify independent prognostic factors to select patients for tailored treatments.

Over the past decades, numerous studies have revealed that several systemic inflammation scores, such as the neutrophil--lymphocyte ratio (NLR) and platelet--lymphocyte ratio (PLR), have important prognostic significance in various malignancies.[@b6-cmar-10-3007]--[@b8-cmar-10-3007] A recent meta-analysis of ten studies provided concrete evidence that high NLR might be correlated with poor outcome in GC.[@b9-cmar-10-3007] In addition, fibrinogen, a 340 kD liver glycoprotein, has been shown to play an essential role in both systemic inflammatory responses and tumor progression.[@b10-cmar-10-3007],[@b11-cmar-10-3007] Many investigators have demonstrated the clinical utility of fibrinogen as a prognostic predictor in various types of malignancies.[@b12-cmar-10-3007],[@b13-cmar-10-3007] Recently, a new scoring system combining preoperative fibrinogen and the NLR (F-NLR) has been demonstrated as a promising prognostic marker for esophageal squamous cell carcinoma.[@b14-cmar-10-3007],[@b15-cmar-10-3007] However, the prognostic role of F-NLR in GC remains unclear.

In the current study, the clinical utility of F-NLR was determined in a large cohort of GC patients after curative surgery.

Patients and methods
====================

Patients' characteristics
-------------------------

We reviewed a clinical database of 1,293 consecutive GC patients after curative surgery at Sun Yat-sen University Cancer Center from October 2000 to September 2012. Our study protocol was conducted in accordance with the standards of the Declaration of Helsinki and approved by the ethical committee of Sun Yat-sen University Cancer Center. Informed consent was deemed unnecessary by the ethical committee, and all information was anonymous. The eighth edition of the tumor--node--metastasis (TNM) criteria was used for tumor staging, and other information was gathered from medical records.

The inclusion criteria of this study were patients who had the following: 1) histologically proven gastric adenocarcinoma, 2) complete data on clinicopathological features and outcome, 3) no neoadjuvant therapy, 4) no multiple primary synchronous malignant tumors and 5) no clinical evidence of infection or other inflammatory disease for at least 1 month before surgery.

Blood specimens were obtained within 1 week before surgery. Plasma fibrinogen concentrations were measured using a CS5100 coagulation analyzer (Sysmex Co., Kobe, Japan). Neutrophils, lymphocytes, platelet counts, and mean platelet volume were evaluated using the XN2000 automated hematology analyzer (Sysmex Co.). By multidisciplinary discussion, 5-fluorouracil-based adjuvant chemotherapy or combined treatment was routinely delivered to stage II--III GC patients without marked comorbidities that would preclude chemotherapy.

Follow-up
---------

The routine follow-up scheme included a clinical review approximately 4 weeks post operation, followed by a complete history, physical examination, blood routine examination, gastroscopy and chest/abdominal/pelvic computerized tomography (CT) imaging, all routinely performed every 3 months during the first postoperative year and every 6 months afterward. The final follow-up date for our study was June 2015. Overall survival (OS) was calculated as the interval from the initial surgery until death or last follow-up.

Calculation of prognostic scores
--------------------------------

The common cutoff threshold for plasma fibrinogen level was 400 g/L as previously described.[@b16-cmar-10-3007],[@b17-cmar-10-3007] Similarly, the NLR and PLR also used widely accepted thresholds.[@b18-cmar-10-3007]--[@b21-cmar-10-3007] The F-NLR was calculated as follows: an F-NLR score of 2, with hyperfibrinogenemia (\>400 mg/dL) and elevated NLR (≥5.0); an F-NLR score of 1, with one abnormal index; an F-NLR score of 0, with no abnormal indices.

Statistical analysis
--------------------

Relationships between the F-NLR score and categorical clinicopathological features were assessed using a two-tailed chi-squared test. Differences between the OS rate generated by the Kaplan--Meier curves were compared using the log-rank test. Prognostic factors were determined by the Cox proportional hazards model. All data were analyzed using SPSS version 19.0 (IBM Corporation, Armonk, NY, USA). A two-sided *P*-value of \<0.05 was regarded as statistically significant. All data have been recorded at Sun Yat-sen University Cancer Center for future reference (number RDDA2017000336).

Results
=======

Among the 1,293 patients (882 men), the median age was 59 (range 19--89) years ([Table 1](#t1-cmar-10-3007){ref-type="table"}). The median duration of follow-up was 35 months. The mean preoperative plasma fibrinogen level (±SD) was 330±91 mg/dL (range 64--802). Patients were classified into two independent groups based on the cutoff threshold of fibrinogen and NLR (low ≤400 mg/dL or high \>400 mg/dL and low \<5 or high ≥5, respectively). Patients with hyperfibrinogenemia and elevated NLR had a poorer OS than those with low plasma fibrinogen levels and NLR (*P*\<0.001 and *P*\<0.001, respectively; [Figure 1](#f1-cmar-10-3007){ref-type="fig"}). In addition, further analysis showed that fibrinogen was positively correlated with NLR (*P*\<0.001). Based on the criteria of the F-NLR score, patients were divided into three independent groups (F-NLR 0, n=986; F-NLR 1, n=279; F-NLR 2, n=28).

The correlation between F-NLR score and clinicopathological features is summarized in [Table 2](#t2-cmar-10-3007){ref-type="table"}. Higher F-NLR scores were more likely found in males (*P*=0.015) and were associated with older age (*P*\<0.001), larger tumor size (*P*\<0.001), tumor location in the upper third of the stomach (*P*=0.005), elevated PLR (*P*\<0.001), deeper tumor invasion (*P*\<0.001) and more lymph node metastasis (*P*=0.003).

In a univariate survival analysis, eight clinicopathological parameters were significant predictors of survival ([Table 3](#t3-cmar-10-3007){ref-type="table"}). After excluding the related parameters, the multivariate analysis identified the F-NLR score as an independent predictor of outcome (HR for F-NLR 1 and F-NLR 2: 1.274, 95% CI 1.043--1.555 and 2.228, 95% CI 1.423--3.487, respectively; *P*\<0.001).

When stratified by TNM stage, the prognostic value of F-NLR was still maintained for stages I--II (*P*\<0.001) and stage III (*P*=0.003; [Figure 2](#f2-cmar-10-3007){ref-type="fig"}). Furthermore, F-NLR also effectively stratified OS irrespective of age, adjuvant chemotherapy administration, tumor location and histological grade (all *P*\<0.05; [Figure 3](#f3-cmar-10-3007){ref-type="fig"}). Of note, F-NLR and TNM stratified 5-year OS from 61% (F-NLR 0) to 15% (F-NLR 2) and from 92% (stage I) to 37% (stage III), respectively, whereas when utilizing both F-NLR and TNM, 5-year OS ranged from 93% (F-NLR 0, TNM I) to 6% (F-NLR 2, TNM III; [Table 4](#t4-cmar-10-3007){ref-type="table"}).

Discussion
==========

The results of the current study show that F-NLR, a newly proposed cumulative score, was an independent prognostic predictor in GC. Of note, its prognostic significance was still maintained in subgroups, including patients diagnosed with TNM stages I--II or stage III, as well as patients who did or did not receive adjuvant chemotherapy. Furthermore, F-NLR also effectively stratified OS irrespective of age, tumor location and histological grade.

Over the past decades, it has become widely accepted that cancer and inflammation are linked.[@b22-cmar-10-3007],[@b23-cmar-10-3007] Indeed, regardless of stage, the maintenance and development of the systemic inflammatory responses have been consistently linked to poorer prognosis.[@b24-cmar-10-3007],[@b25-cmar-10-3007] Although many organ systems act in the activation of systemic inflammatory responses, the common measurements of the magnitude of activation are circulating cellular components and acute-phase proteins. In particular, several common peripheral blood-derived inflammation-based scores, such as the Glasgow Prognostic Score (GPS), NLR, and PLR, have been demonstrated as promising prognostic predictors in various malignancies.[@b26-cmar-10-3007]--[@b28-cmar-10-3007] However, the measurement of serum C-reactive protein was not routinely taken in our hospital before 2005, and therefore, the prognostic value of GPS was not examined in the current study.

In addition, much attention has been paid to the association between hypercoagulation and malignancy progression in recent years.[@b29-cmar-10-3007],[@b30-cmar-10-3007] Accumulating evidence indicates that the activation of the coagulation cascade plays a key pathophysiological role during tumor progression.[@b31-cmar-10-3007] Fibrinogen, as an important component of the coagulation cascade, has been demonstrated as an essential regulator in both the systemic inflammatory response and tumor progression. First, fibrinogen provides a stable framework for the tumor extracellular matrix, which may promote tumor angiogenesis and enhance tumor cell adhesion, migration and invasion.[@b32-cmar-10-3007]

Moreover, as an acute-phase protein, fibrinogen is released in response to infection or systemic inflammation. It may mediate the initial adhesion of leukocytes to endothelial cells and the release of pro-inflammatory cytokines, thereby leading to tumor cell proliferation and progression.[@b33-cmar-10-3007] Recent studies have presented evidence that fibrinogen correlates with tumor progression, poor response to chemotherapy and adverse clinical outcome in various types of cancer.[@b12-cmar-10-3007],[@b34-cmar-10-3007]

Recently, a newly proposed scoring system (F-NLR) has garnered increasing attention in esophageal squamous cell carcinoma. Kijima et al[@b14-cmar-10-3007] proved that the F-NLR score had clinical potential as a predictor of therapeutic effects and outcomes in advanced esophageal squamous cell carcinoma. Another study, which evaluated 238 patients undergoing esophagectomy for esophageal squamous cell carcinoma, reported that the F-NLR score was a promising predictive marker of tumor progression and prognosis.[@b15-cmar-10-3007]

However, in GC, the utility of the F-NLR score has not yet been systematically analyzed. Although Arigami et al[@b35-cmar-10-3007] found that the F-NLR score was an independent prognostic predictor in advanced GC, they only enrolled 68 patients with distant metastatic GC including locally advanced tumor and recurrent disease. The enrolled patients underwent nonuniform treatment, including surgery, chemotherapy or chemoradiotherapy. Because of the limited cases, they did not perform subgroup analyses to further verify the prognostic value. However, we aimed to determine whether the F-NLR score could better predict survival of patients after curative resection for stage I--III GC. Therefore, we performed a large-scale retrospective study and found that the F-NLR score could independently predict survival after curative resection of GC. As shown in [Figures 1](#f1-cmar-10-3007){ref-type="fig"}--[2](#f2-cmar-10-3007){ref-type="fig"}, the F-NLR score can effectively divide patients into three independent groups. Undoubtedly, F-NLR score could identify more high-risk patients than fibrinogen or NLR alone. Overall, the data suggest that the F-NLR score may provide more potent prognostic value than the individual indices. Furthermore, higher F-NLR scores were associated with larger tumor size, deeper tumor invasion, and lymph node metastasis. This observation was in line with previous studies that indicated that the F-NLR score was significantly correlated with tumor progression and aggressive biological behavior.[@b14-cmar-10-3007],[@b15-cmar-10-3007] In subgroup analyses, the F-NLR score still exhibited potential prognostic value, as shown in [Figures 2](#f2-cmar-10-3007){ref-type="fig"} and [3](#f3-cmar-10-3007){ref-type="fig"}. Indeed, our conclusions have been strengthened by the subgroup analyses. Moreover, the combination of F-NLR and TNM stage increased the range of survival compared to either F-NLR or TNM alone. Therefore, the inclusion of some valuable clinicopathological features as additional prognostic factors in TNM staging does not negate the role of host characteristics, such as the F-NLR score, in effective prognostic stratification. Indeed, F-NLR could identify more high-risk patients than the current TNM staging system alone. Thus, in clinical practice, patients with higher F-NLR scores may need better followup and lower thresholds for early intervention. On the other hand, in patients with F-NLR 2, it might be that preoperative early intervention should be given as a first-line treatment. Further prospective clinical trials are still needed to confirm these results.

Our study has several limitations. First of all, it is a retrospective study including only one institution, which may lead to a selection bias. Second, with limited data availability, some possible confounding factors, such as cardiovascular and kidney disease, probably influence the fibrinogen levels but cannot be analyzed. Third, we lack the follow-up information on disease-free survival, and our conclusions may be strengthened by using other survival measures.

Conclusion
==========

The F-NLR score is an independent predictor of survival in GC, and it may have important clinical utility for identifying patients at high risk and guiding the administration of individualized treatment. Furthermore, the components of the F-NLR score are objectively measured and routinely available, which makes our findings potentially applicable to clinical practice.

The authors are grateful to the people who kindly cooperated in our study.
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![Kaplan--Meier survival curves according to preoperative fibrinogen (**A**) and the NLR (**B**).\
**Abbreviations:** NLR, neutrophil--lymphocyte ratio; OS, overall survival.](cmar-10-3007Fig1){#f1-cmar-10-3007}

![OS based on the F-NLR score in patients with stage I--III (**A**), stage I--II (**B**) and stage III (**C**) GC.\
**Note:** F-NLR, combination of fibrinogen and the NLR.\
**Abbreviations:** GC, gastric cancer; NLR, neutrophil--lymphocyte ratio; OS, overall survival.](cmar-10-3007Fig2){#f2-cmar-10-3007}

![OS based on the F-NLR score in patients aged \<60 years (**A**), patients aged ≥60 years (**B**), patients without adjuvant chemotherapy (**C**) and patients with adjuvant chemotherapy (**D**).\
**Note:** F-NLR, combination of fibrinogen and the NLR.\
**Abbreviations:** NLR, neutrophil--lymphocyte ratio; OS, overall survival.](cmar-10-3007Fig3){#f3-cmar-10-3007}

###### 

The clinicopathological features of 1,293 GC patients

  Features                 Patients, n (%)
  ------------------------ -----------------
  Age (years)              
   \<60                    685 (53.0)
   ≥60                     608 (47.0)
  Sex                      
   Female                  411 (31.8)
   Male                    882 (68.2)
  Tumor size (cm)          
   \<5                     720 (55.7)
   ≥5                      573 (44.3)
  Tumor location           
   Upper third             501 (38.7)
   Middle third            268 (20.7)
   Lower third             524 (40.5)
  Histological grade       
   Well differentiated     219 (16.9)
   Poorly differentiated   1,074 (83.1)
  NLR                      
   \<5.0                   1,221 (94.4)
   ≥5.0                    72 (5.6)
  Fibrinogen (mg/dL)       
   ≤400                    1,030 (79.7)
   \>400                   263 (20.3)
  PLR                      
   \<150                   792 (61.3)
   ≥150 and ≤300           438 (33.9)
   \>300                   63 (4.9)
  MPV (fL)                 
   \<10                    981 (77.1)
   ≥10                     292 (22.9)
  F-NLR                    
   0                       986 (76.3)
   1                       279 (21.6)
   2                       28 (2.2)
  TNM stage                
   I                       218 (16.9)
   II                      322 (24.9)
   III                     753 (58.2)
  Adjuvant chemotherapy    
   No                      498 (38.5)
   Yes                     795 (61.5)

**Note:** F-NLR, combination of fibrinogen and the NLR.

**Abbreviations:** GC, gastric cancer; MPV, mean platelet volume; NLR neutrophil--lymphocyte ratio; PLR, platelet--lymphocyte ratio; TNM, tumor--node--metastasis.

###### 

The clinicopathological characteristics stratified by the F-NLR score

  -------------------------------------------------------------------------------------------------------------------
  Characteristics          F-NLR 0\   F-NLR 1\   F-NLR 2\   *P*-value[\*](#tfn3a-cmar-10-3007){ref-type="table-fn"}
                           (n=986)    (n=279)    (n=28)     
  ------------------------ ---------- ---------- ---------- ---------------------------------------------------------
  Age (years)                                               \<**0.001**

   \<60                    558        118        9          

   ≥60                     428        161        19         

  Sex                                                       **0.015**

   Female                  329        79         3          

   Male                    657        200        25         

  Tumor size (cm)                                           \<**0.001**

   \<5                     606        105        9          

   ≥5                      380        174        19         

  Tumor location                                            **0.005**

   Upper third             357        128        16         

   Middle third            212        49         7          

   Lower third             417        102        5          

  Histological grade                                        0.093

   Well differentiated     155        57         7          

   Poorly differentiated   831        222        21         

  PLR                                                       \<**0.001**

   \<150                   678        113        1          

   ≥150 and ≤300           285        138        15         

   \>300                   23         28         12         

  MPV (fL)                                                  0.069

   \<10                    733        225        23         

   ≥10                     237        51         4          

  Tumor depth                                               \<**0.001**

   T1                      142        13         0          

   T2                      120        19         1          

   T3                      211        64         8          

   T4                      513        183        19         

  Lymph node                                                **0.003**

   N0                      347        66         4          

   N1                      148        49         8          

   N2                      171        51         5          

   N3                      320        113        11         
  -------------------------------------------------------------------------------------------------------------------

**Notes:**

F-NLR, combination of fibrinogen and the NLR.

Values in bold refer to *P*-value with significance (*P*\<0.05).

**Abbreviations:** MPV, mean platelet volume; NLR, neutrophil--lymphocyte ratio; PLR, platelet--lymphocyte ratio.

###### 

Univariate and multivariate analyses of prognostic factors in 1,296 patients with GC

  Factors                  Univariate analysis      Multivariate analysis                           
  ------------------------ ------------------------ ----------------------- ----------------------- -------------
  Age (years)                                       \<**0.001**                                     \<**0.001**
   \<60                    1.00                                             1.00                    
   ≥60                     1.490 (1.252, 1.774)                             1.467 (1.228, 1.752)    
  Sex                                               0.667                                           
   Female                  1.00                                                                     
   Male                    1.042 (0.864, 1.256)                                                     
  Tumor size (cm)                                   \<**0.001**                                     0.988
   \<5                     1.00                                             1.00                    
   ≥5                      1.718 (1.443, 2.046)                             0.999 (0.833, 1.198)    
  Tumor location                                    \<**0.001**                                     \<**0.001**
   Upper third             1.00                                             1.00                    
   Middle third            0.673 (0.535, 0.847)     **0.001**               0.800 (0.632, 1.012)    0.062
   Lower third             0.456 (0.373, 0.558)     \<**0.001**             0.602 (0.489, 0.742)    \<**0.001**
  Histological grade                                **0.027**                                       **0.032**
   Well differentiated     1.00                                             1.00                    
   Poorly differentiated   1.328 (1.032, 1.710)                             1.327 (1.024, 1.720)    
  NLR                                               \<**0.001**                                     
   \<5.0                   1.00                                                                     
   ≥5.0                    2.313 (1.707, 3.134)                                                     
  Fibrinogen (mg/dL)                                \<**0.001**                                     
   ≤400                    1.00                                                                     
   \>400                   1.618 (1.330, 1.969)                                                     
  PLR                                               0.069                                           
   \<150                   1.00                                                                     
   ≥150 and ≤300           1.210 (1.007, 1.454)     **0.042**                                       
   \>300                   1.325 (0.910, 1.930)     0.142                                           
  MPV (fL)                                          0.571                                           
   \<10                    1.00                                                                     
   ≥10                     0.940 (0.757, 1.166)                                                     
  F-NLR                                             \<**0.001**                                     \<**0.001**
   0                       1.00                                             1.00                    
   1                       1.619 (1.331, 1.969)     \<**0.001**             1.274 (1.043, 1.555)    **0.008**
   2                       3.326 (2.139, 5.172)     \<**0.001**             2.228 (1.423, 3.487)    \<**0.001**
  TNM stage                                         \<**0.001**                                     \<**0.001**
   I                       1.00                                             1.00                    
   II                      3.006 (1.764, 5.122)     \<**0.001**             2.525 (1.475, 4.321)    **0.008**
   III                     11.059 (6.807, 17.967)   \<**0.001**             9.129 (5.565, 14.977)   \<**0.001**
  Adjuvant chemotherapy                             0.373                                           
   No                      1.00                                                                     
   Yes                     0.922 (0.771, 1.102)                                                     

**Notes:** F-NLR, combination of fibrinogen and the NLR.

Values in bold refer to *P*-value with significance (*P*\<0.05).

**Abbreviations:** GC, gastric cancer; MPV, mean platelet volume; NLR, neutrophil--lymphocyte ratio; PLR, platelet--lymphocyte ratio; TNM, tumor--node--metastasis.

###### 

Relationships between F-NLR and 5-year OS in patients undergoing curative resection for stage I--III GC

  Characteristics   TNM stage I   TNM stage II   TNM stage III   TNM stages I--III                         
  ----------------- ------------- -------------- --------------- ------------------- ----- -------- ------ --------
  F-NLR             218           92 (2)         322             74 (3)              753   37 (2)   1293   56 (2)
  0                 195           93 (2)         249             80 (3)              542   41 (2)   986    61 (2)
  1                 23            89 (8)         66              53 (8)              190   32 (4)   279    42 (4)
  2                 0             NA             7               44 (2)              21    6 (6)    28     15 (8)

**Notes:** The values are expressed as n or percentage (standard error). Survival is not calculated if n≤10. F-NLR, combination of fibrinogen and the NLR.

**Abbreviations:** GC, gastric cancer; NA, not applicable; NLR, neutrophil--lymphocyte ratio; OS, overall survival.
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